<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0002725'>Systemic lupus erythematosus</z:hpo> (SLE) is an autoimmune <z:chebi fb="67" ids="50114">oestrogen</z:chebi>-mediated disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an autoimmune acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>These two conditions may co-exist and are most frequently diagnosed in young women </plain></SENT>
<SENT sid="3" pm="."><plain>Hormonal contraception may promote <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> activity and thromboses </plain></SENT>
<SENT sid="4" pm="."><plain>Medical practitioners may not know what advice to give these women regarding contraception </plain></SENT>
<SENT sid="5" pm="."><plain>OBJECTIVES: To determine the past and present contraceptive practices of women with SLE and/or APS, and to establish the incidence of complications related to use of various contraceptives </plain></SENT>
<SENT sid="6" pm="."><plain>Also, the contraceptive information given to women following diagnosis was evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>Study design: Observational questionnaire-based study of 86 women with SLE and/or APS attending the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e>/<z:hpo ids='HP_0100724'>Thrombophilia</z:hpo> Clinics at St </plain></SENT>
<SENT sid="8" pm="."><plain>Thomas' Hospital </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: One of the 19 (5%) women with SLE using the combined oral contraceptive pill (COCP) at the time of diagnosis reported a severe <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> 'flare' </plain></SENT>
<SENT sid="10" pm="."><plain>Seven of the 32 (22%) women with APS using the COCP suffered from thromboses during use </plain></SENT>
<SENT sid="11" pm="."><plain>There were no problems specific to women with SLE and/or APS using any other form of contraception </plain></SENT>
<SENT sid="12" pm="."><plain>Thirty-nine (45%) women received no contraceptive information following their diagnosis, 37 (46%) were told to avoid the COCP due to the increase in <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> 'flare' and/or thromboses </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: There is no clinically significant association between COCP use and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> 'flare' </plain></SENT>
<SENT sid="14" pm="."><plain>The high incidence of thromboses in women with APS using the COCP containing either second or third generation <z:chebi fb="13" ids="50745">progestogens</z:chebi> suggests that these women should be advised against using this form of contraception </plain></SENT>
<SENT sid="15" pm="."><plain>Women with SLE and/or APS should be given more information about contraceptive issues </plain></SENT>
</text></document>